# Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

> **NCT02926196** · PHASE3 · COMPLETED · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 474 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** MSB0010718C

## Key facts

- **NCT ID:** NCT02926196
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2024-06
- **Final completion:** 2025-10-09
- **Target enrollment:** 474 (ACTUAL)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926196, "Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02926196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*